Evidence map›Paper›PMID 38727391›Full record

ReviewNanomaterials (Basel, Switzerland)2024

Metal-Organic Framework Nanomaterials as a Medicine for Catalytic Tumor Therapy: Recent Advances.

Jiaojiao Zhang, Meiyu Li, Maosong Liu, Qian Yu, Dengfeng Ge, Jianming Zhang

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Influence of Deposition Temperature on Cu-BDC Surface-Anchored Metal-Organic Framework Formation.The journal of physical chemistry. C, Nanomaterials and interfaces · 2025
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiaojiao ZhangSchool of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang 212013, China.
Meiyu LiSchool of Life Science, Jiangsu University, Zhenjiang 212013, China.
Maosong LiuSchool of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang 212013, China.ORCID 0000-0002-6936-473X
Qian YuSchool of Life Science, Jiangsu University, Zhenjiang 212013, China.ORCID 0000-0002-6117-0463
Dengfeng GeShengli Oilfield Central Hospital, 31 Ji'nan Rd, Dongying 257034, China.
Jianming ZhangSchool of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang 212013, China.ORCID 0000-0002-7752-1192

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomaterials, with unique physical, chemical, and biocompatible properties, have attracted significant attention as an emerging active platform in cancer diagnosis and treatment. Amongst them, metal-organic framework (MOF) nanostructures are particularly promising as a nanomedicine due to their exceptional surface functionalities, adsorption properties, and organo-inorganic hybrid characteristics. Furthermore, when bioactive substances are integrated into the structure of MOFs, these materials can be used as anti-tumor agents with superior performance compared to traditional nanomaterials. In this review, we highlight the most recent advances in MOFs-based materials for tumor therapy, including their application in cancer treatment and the underlying mechanisms.

Indexed as

metal–organic frameworksnanomedicinesynergetic therapytumor therapy

Identifiers

PMID38727391
PMCPMC11085591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.